Alternatives to ImmunoVec, .

Developing advanced cell culture media and bioprocessing solutions for cell and gene therapy.

Develops advanced gene editing and cell therapy solutions for rare genetic diseases.

Biotechnology company developing cell and gene therapies for serious diseases.

Developing engineered biologics to harness the immune system for disease treatment.

Clinical-stage genetic medicine company developing AAV-mediated treatments for cardiovascular and Alzheimer's diseases.

Biotechnology company developing gene therapies and regenerative medicine for heart disease.

A clinical-stage oncology company developing DNA interference (DNAi) based cancer therapies.

Clinical-stage biotech company developing AAV gene therapies for rare and retinal diseases.

Clinical-stage biotechnology company developing Antibody Oligonucleotide Conjugates (AOCs) for serious diseases.

Gene therapy company developing transformative treatments for severe genetic diseases.

Gene therapy company developing treatments for rare inherited diseases.

Ridge Bio is developing a novel gene therapy platform for treating rare genetic diseases.

Clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.

Develops novel protein engineering and directed evolution technologies for therapeutic discovery.

Develops and manufactures biologics for therapeutic applications.

Developing novel therapeutics for challenging diseases using advanced biological insights.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Clinical-stage biopharma developing precisely designed cancer therapeutics using a proprietary cell-free protein synthesis platform.

Biopharmaceutical company developing therapies for neurodegenerative diseases, focusing on crossing the blood-brain barrier.

Leveraging the adaptive immune system to diagnose and treat disease.